Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2015)

First Author: McInnes IB
Attributed to:  Infrastructure for collaboration: Leeds MRC Medical Bioinformatics Centre funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(15)61134-5

PubMed Identifier: 26135703

Publication URI: http://europepmc.org/abstract/MED/26135703

Type: Journal Article/Review

Volume: 386

Parent Publication: Lancet (London, England)

Issue: 9999

ISSN: 0140-6736